NCT05320627

Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 150 (actual)
• Sponsor: China National Center for Cardiovascular Diseases · Other Government
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

Based on the population pharmacokinetic data of Chinese patients with atrial fibrillation, the study will evaluate the suitability of the ENGAGE Population Pharmacokinetics model of edoxaban in patients with atrial fibrillation in China, and build a predictive dose model of edoxaban that meets the characteristics of Chinese people. It can provide perfect individualized dosing plan improves clinical efficacy and reduces adverse drug reactions.

Detailed description

This is an open label study. Male or female patients with non-valvular atrial fibrillation (NVAF) with age ≥20 years, and meeting the indications of edoxaban are potentially eligible for the study. Patients receive Edoxaban 15mg、30mg or 60mg according to the criteria as following: 1. Patients with severe renal insufficiency (15ml/min ≤ CrCl \<30ml/min), 15mg quaque die (QD) 2. Patients with normal or mild renal insufficiency (CrCl ≥50ml/min), 60mg QD 3. Patients with moderate renal insufficiency (30ml/min ≤ CrCl \<50ml/min), weight ≤60kg or combined use of P-gp inhibitors (such as dronedarone，ketoconazole, erythromycin, etc), 30mg QD. Patients will receive clinical evaluation at screening period, 4 weeks、8 weeks and 12 weeks after administration with Edoxaban. The following clinical evaluation items were included: body weight, vital signs (blood pressure and heart rate), CHADS2-VAS score, concomitant medication, ECG and echocardiogram, laboratory examination, safety evaluation (thromboembolic events, bleeding events, death) during treatment. Additional blood samples are collected for pharmacokinetic evaluation at screening period, pre-dose, 2±1h and 6±1h after administration at 4-, 8-, and 12-week visit, and for pharmacodynamic evaluation (FXa) at screening period, pre-dose after administration at 4-, 8-, 12-week visit. The population pharmacokinetics of Edoxaban in Chinese patients with non-valvular atrial fibrillation will be determined after 12weeks clinical observation. The ENGAGE PopPK model suitable in Chinese Patients with Non-Valvular Atrial Fibrillation will be established. Safety outcomes (thromboembolic events, bleeding events, death) will be evaluated.

Conditions

• Non-Valvular Atrial Fibrillation

Interventions

Type	Name	Description
DRUG	Edoxaban	Eligible patients will receive Edoxaban tablet once a day for 12 weeks

Timeline

• Start date: 2022-03-30
• Primary completion: 2024-08-30
• Completion: 2024-10-30
• First posted: 2022-04-11
• Last updated: 2026-03-23

Locations

1 site across 1 country: China